Clinical spectrum of encephalitis associated with antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: Case series and review of the literature

JAMA Neurology

Volumn 72, Issue 10, 2015, Pages 1163-1169

  Joubert, Bastien ^a,b,c   Kerschen, Philippe ^d,e   Zekeridou, Anastasia ^f   Desestret, Virginie ^a,b,c   Rogemond, Véronique ^a,b,c,f   Chaffois, Marie Océane ^a,b,c,f   Ducray, François ^a,b,c,f   Larrue, Vincent ^g   Daubail, Benoit ^h   Idbaih, Ahmed ⁱ   Psimaras, Dimitri ^f,i   Antoine, Jean Christophe ^f,j   Delattre, Jean Yves ^f,i   Honnorat, Jérôme ^a,b,c,f  

^a UNIVERSITÉ LYON 1   (France)

^b CNRS   (France)

^c HÔPITAL NEUROLOGIQUE   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Hospices Civils de Lyon   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j SERVICE DE NEUROLOGIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID RECEPTOR ANTIBODY; AMPA RECEPTOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AUTOANTIBODY;

ADULT; AGED; ALLERGIC ENCEPHALITIS; AMNESIA; ANIMAL TISSUE; ANTIBODY SCREENING; ARTICLE; BREAST CANCER; CANCER PREVALENCE; CEREBELLUM DEGENERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONFUSION; DELUSION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EPILEPSY; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN CELL; INSOMNIA; LUNG CARCINOMA; MALE; MOTOR DYSFUNCTION; NONHUMAN; ONCOLOGICAL PARAMETERS; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; RAT; SEIZURE; THYMUS CANCER; VERY ELDERLY; AUTOIMMUNE DISEASE; BLOOD; CASE REPORT; COMPLICATION; ENCEPHALITIS; HASHIMOTO DISEASE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PARANEOPLASTIC NEUROPATHY; SEIZURES;

AGED; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; ENCEPHALITIS; FEMALE; HASHIMOTO DISEASE; HUMANS; LIMBIC ENCEPHALITIS; MALE; MIDDLE AGED; RECEPTORS, AMPA; SEIZURES;

EID: 84944061836     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1715     Document Type: Article

References (20)

1. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann NYAcad Sci. 2015;1338:94-114.
2. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424-434.
3. Graus F, Boronat A, Xifró X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology. 2010;74(10):857-859.
4. Bataller L, Galiano R, García-Escrig M, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology. 2010;74(3):265-267.
5. Wei YC, Liu CH, Lin JJ, et al. Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol. 2013;261(1-2):129-133.
6. Gleichman AJ, Panzer JA, Baumann BH, Dalmau J, Lynch DR. Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. Ann Clin Transl Neurol. 2014;1(3):180-189.
7. 18FDG-PET in anti-AMPA receptor limbic encephalitis. J Neuroimmunol. 2014;271(1-2):53-55.
8. Dogan Onugoren M, Deuretzbacher D, Haensch CA, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series [published online October 9, 2014]. J Neurol Neurosurg Psychiatry. 2014; jnnp-2014-308814.
9. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327-340.
10. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131(pt 10):2553-2563.
11. Malter MP, Frisch C, Schoene-Bake JC, et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol. 2014;261(9):1695-1705.
12. Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135(pt 5):1622-1638.
13. Wagner J, Witt JA, Helmstaedter C, et al. Automated volumetry of the mesiotemporal structures in antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry. 2015;86(7):735-742.
14. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.
15. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77(6):589-593.
16. Camdessanché JP, Streichenberger N, Cavillon G, et al. Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. Eur J Neurol. 2011;18(6):929-931.
17. Peng X, Hughes EG, Moscato EH, Parsons TD, Dalmau J, Balice-Gordon RJ. Cellular plasticity induced by anti-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol. 2015;77(3):381-398.
18. Ha JC, Richman DP. Myasthenia gravis and related disorders: pathology and molecular pathogenesis. Biochim Biophys Acta. 2015;1852(4):651-657.
19. Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72(6):902-911.
20. Feichtinger M, Wiendl H, Körner E, et al. No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3-antibodies. Seizure. 2006;15(5):350-354.